microRNA-205 in prostate cancer: Overview to clinical translation.
Biomarker
Chemosensitization
Chemotherapy
Prostate cancer
Radiation
microRNA
Journal
Biochimica et biophysica acta. Reviews on cancer
ISSN: 1879-2561
Titre abrégé: Biochim Biophys Acta Rev Cancer
Pays: Netherlands
ID NLM: 9806362
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
06
07
2022
revised:
27
09
2022
accepted:
27
09
2022
pubmed:
4
10
2022
medline:
16
11
2022
entrez:
3
10
2022
Statut:
ppublish
Résumé
Prostate cancer (PrCa) is the most common type of cancer among men in the United States. The metastatic and advanced PrCa develops drug resistance to current regimens which accounts for the poor management. microRNAs (miRNAs) have been well-documented for their diagnostic, prognostic, and therapeutic roles in various human cancers. Recent literature confirmed that microRNA-205 (miR-205) has been established as one of the tumor suppressors in PrCa. miR-205 regulates number of cellular functions, such as proliferation, invasion, migration/metastasis, and apoptosis. It is also evident that miR-205 can serve as a key biomarker in diagnostic, prognostic, and therapy of PrCa. Therefore, in this review, we will provide an overview of tumor suppressive role of miR-205 in PrCa. This work also outlines miR-205's specific role in targeted mechanisms for chemosensitization and radiosensitization in PrCa. A facile approach of delivery paths for successful clinical translation is documented. Together, all these studies provide a novel insight of miR-205 as an adjuvant agent for reducing the widening gaps in clinical outcome of PrCa patients.
Identifiants
pubmed: 36191828
pii: S0304-419X(22)00134-2
doi: 10.1016/j.bbcan.2022.188809
pmc: PMC9996811
mid: NIHMS1873294
pii:
doi:
Substances chimiques
MicroRNAs
0
MIRN205 microRNA, human
0
Types de publication
Journal Article
Review
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
188809Subventions
Organisme : NCI NIH HHS
ID : R01 CA206069
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA210192
Pays : United States
Organisme : NIGMS NIH HHS
ID : SC1 GM139727
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Neeraj Chauhan; Anjali Manojkumar; Meena Jaggi; Subhash C. Chauhan; Murali M. Yallapu.
Références
J Cell Sci. 2010 Feb 15;123(Pt 4):606-18
pubmed: 20103531
Oncogene. 2014 Jan 9;33(2):135-47
pubmed: 23455326
J Urol. 2013 Mar;189(3):1110-6
pubmed: 22999998
Mol Cancer Res. 2014 Feb;12(2):250-63
pubmed: 24337069
Antioxid Redox Signal. 2014 Mar 1;20(7):1045-59
pubmed: 23924028
Eur J Cancer Prev. 2009 Feb;18(1):50-5
pubmed: 19077565
PLoS One. 2019 Nov 22;14(11):e0224071
pubmed: 31756185
Proc Natl Acad Sci U S A. 2006 Feb 21;103(8):2695-700
pubmed: 16477001
Cancers (Basel). 2018 Aug 25;10(9):
pubmed: 30149628
Noncoding RNA. 2019 Nov 19;5(4):
pubmed: 31752366
Biochem Biophys Res Commun. 2014 Feb 7;444(2):270-5
pubmed: 24462768
Nucleic Acids Res. 2019 Jan 8;47(D1):D155-D162
pubmed: 30423142
Oncol Rep. 2013 Dec;30(6):2897-902
pubmed: 24084898
Cancer Res. 2008 Aug 1;68(15):6162-70
pubmed: 18676839
Oncol Rep. 2010 Jun;23(6):1625-33
pubmed: 20428818
Oncogene. 2012 Oct 11;31(41):4460-71
pubmed: 22266859
Cancer Gene Ther. 2009 Mar;16(3):206-16
pubmed: 18949015
Mol Cancer. 2010 Jan 21;9:12
pubmed: 20092645
J Biol Chem. 2013 Feb 1;288(5):3275-88
pubmed: 23239884
Cell Death Dis. 2016 Jun 30;7(6):e2291
pubmed: 27362808
J Clin Oncol. 2009 Apr 20;27(12):2030-7
pubmed: 19273703
Oncogene. 2003 Feb 27;22(8):1164-80
pubmed: 12606943
Oncol Lett. 2018 May;15(5):7571-7578
pubmed: 29725462
Dev Biol. 2007 Feb 1;302(1):1-12
pubmed: 16989803
Nat Rev Urol. 2011 Jun 21;8(8):428-39
pubmed: 21691304
Acta Biochim Biophys Sin (Shanghai). 2010 Jun 15;42(6):363-9
pubmed: 20539944
Curr Pharm Biotechnol. 2014;15(9):829-38
pubmed: 25335533
Cell Death Dis. 2020 Nov 15;11(11):980
pubmed: 33191398
Annu Rev Cell Dev Biol. 1997;13:513-609
pubmed: 9442882
J Hum Genet. 2018 Feb;63(2):195-205
pubmed: 29196733
Cancer Res. 2009 Feb 1;69(3):879-86
pubmed: 19176371
J Exp Clin Cancer Res. 2019 Feb 4;38(1):51
pubmed: 30717752
N Engl J Med. 2018 Feb 15;378(7):645-657
pubmed: 29412780
Eur J Cell Biol. 2013 Feb;92(2):54-60
pubmed: 23279926
Cancer Cell Int. 2003 Oct 14;3(1):17
pubmed: 14613514
Mol Med Rep. 2018 Sep;18(3):3242-3250
pubmed: 30066866
Br J Cancer. 2013 Apr 30;108(8):1668-76
pubmed: 23571738
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6116-24
pubmed: 17062688
J Biol Chem. 2011 May 13;286(19):16606-14
pubmed: 21454583
Int J Pharm Investig. 2015 Oct-Dec;5(4):179-81
pubmed: 26682187
Expert Rev Anticancer Ther. 2011 Jun;11(6):859-69
pubmed: 21707283
Oncogene. 2008 Oct 23;27(49):6365-75
pubmed: 18679417
Prostate. 2010 Feb 15;70(3):297-304
pubmed: 19827049
Mod Pathol. 2004 Mar;17(3):316-27
pubmed: 14976541
Intern Med J. 2014 May;44(5):433-40
pubmed: 24816306
Expert Opin Ther Targets. 2009 Dec;13(12):1439-48
pubmed: 19839716
Small. 2011 Nov 18;7(22):3158-62
pubmed: 21922667
J Urol. 1997 Oct;158(4):1427-30
pubmed: 9302136
Oncogene. 2013 Jun 6;32(23):2891-9
pubmed: 22869146
Asian Pac J Cancer Prev. 2014;15(2):577-83
pubmed: 24568460
Int J Oncol. 2013 Jul;43(1):307-14
pubmed: 23612742
Int J Urol. 2015 Sep;22(9):867-77
pubmed: 26059417
Oncogene. 2013 Jan 17;32(3):277-85
pubmed: 22391564
Cell Death Differ. 2012 Nov;19(11):1750-60
pubmed: 22555458
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
PLoS One. 2014 Nov 17;9(11):e113039
pubmed: 25401698
Int J Mol Sci. 2020 Dec 22;22(1):
pubmed: 33375067
Biochem Biophys Res Commun. 2009 Oct 16;388(2):400-5
pubmed: 19665999
J Ovarian Res. 2017 May 5;10(1):33
pubmed: 28476165
Clin Cancer Res. 2012 Dec 15;18(24):6742-7
pubmed: 22927485
Adv Exp Med Biol. 2018;1095:101-110
pubmed: 30229551
Cell Res. 2009 Apr;19(4):439-48
pubmed: 19238171
Cancer. 2010 Dec 15;116(24):5637-49
pubmed: 20737563
Mol Oncol. 2012 Aug;6(4):458-72
pubmed: 22578566
BMC Cancer. 2021 Jan 5;21(1):15
pubmed: 33402116
Future Oncol. 2016 Feb;12(3):399-411
pubmed: 26768791
Nucleic Acids Res. 2009 Jul;37(Web Server issue):W273-6
pubmed: 19406924
Oncol Rep. 2015 Oct;34(4):2163-70
pubmed: 26239614
Int J Cancer. 2011 Feb 1;128(3):608-16
pubmed: 20473869
Exp Biol Med (Maywood). 2007 Oct;232(9):1121-9
pubmed: 17895520
Oncogene. 2014 Jan 16;33(3):269-78
pubmed: 23455327
Urol Oncol. 2007 Sep-Oct;25(5):387-92
pubmed: 17826655
PLoS One. 2013 Oct 22;8(10):e76994
pubmed: 24167554
Int J Mol Sci. 2013 Oct 29;14(11):21414-34
pubmed: 24173237
Urology. 2011 Dec;78(6):1224-8
pubmed: 21908026
J Natl Cancer Inst. 2009 Mar 18;101(6):374-83
pubmed: 19276453
Biomed Res Int. 2020 Oct 29;2020:6037434
pubmed: 33178832
Oncotarget. 2015 Apr 20;6(11):8434-53
pubmed: 25726529
Mol Med Rep. 2017 Aug;16(2):1431-1438
pubmed: 28627687
Adv Drug Deliv Rev. 2014 Feb;66:74-89
pubmed: 24270010
Methods Mol Biol. 2011;732:69-88
pubmed: 21431706
Asian J Androl. 2013 Nov;15(6):735-41
pubmed: 23974361
Cell Cycle. 2018;17(24):2802-2818
pubmed: 30526248
World J Gastroenterol. 2019 Jul 28;25(28):3775-3786
pubmed: 31391772
J Urol. 2012 Mar;187(3):795-801
pubmed: 22245323
Clin Cancer Res. 2007 Dec 1;13(23):7003-11
pubmed: 18056176
Sci Rep. 2021 Mar 11;11(1):5660
pubmed: 33707587
Cancer Metastasis Rev. 2014 Sep;33(2-3):469-96
pubmed: 24445654
Biochem Biophys Res Commun. 2009 Jun 5;383(3):280-5
pubmed: 19302977
EMBO J. 2002 Aug 1;21(15):4037-48
pubmed: 12145204
Cancer Res. 2007 Jul 1;67(13):6130-5
pubmed: 17616669
Oncol Lett. 2018 Oct;16(4):4331-4336
pubmed: 30214569
Cell Cycle. 2012 Aug 15;11(16):3067-78
pubmed: 22871739
Hippokratia. 2010 Oct;14(4):236-40
pubmed: 21311629
Biochem Pharmacol. 2014 Feb 15;87(4):579-97
pubmed: 24370341
Am J Pathol. 2012 Dec;181(6):2188-201
pubmed: 23041061
Cancer Res. 2009 Mar 15;69(6):2287-95
pubmed: 19244118
Brief Funct Genomics. 2018 Jan 1;17(1):49-63
pubmed: 28968850
Eur Urol. 2013 Dec;64(6):920-8
pubmed: 23465517
J Mater Chem B. 2019 Feb 28;7(8):1209-1225
pubmed: 32255160
Int J Cancer. 2011 Mar 15;128(6):1327-34
pubmed: 20473948
Eur Rev Med Pharmacol Sci. 2014 Aug;18(16):2275-82
pubmed: 25219826
J Control Release. 2019 Nov 10;313:80-95
pubmed: 31622695
Oncol Lett. 2019 Jan;17(1):843-848
pubmed: 30655837
Cancer Cell. 2008 Mar;13(3):188-92
pubmed: 18328423
Gene Ther. 2000 Dec;7(23):2051-7
pubmed: 11175318
Curr Cancer Drug Targets. 2014;14(7):621-37
pubmed: 25308719
BMC Fam Pract. 2002 Oct 24;3:19
pubmed: 12398793
Ann Oncol. 2007 Nov;18(11):1765-73
pubmed: 17426060
Cell Death Dis. 2010 Dec 09;1:e105
pubmed: 21368878
Immunity. 2005 Jan;22(1):131-42
pubmed: 15664165
Biochim Biophys Acta. 2002 Jun 21;1602(2):114-30
pubmed: 12020799
RNA Biol. 2010 May-Jun;7(3):300-4
pubmed: 20436283
Science. 2003 Mar 7;299(5612):1540
pubmed: 12624257
BJU Int. 2020 Aug;126(2):218-224
pubmed: 32715604
Trends Cell Biol. 2015 Nov;25(11):675-686
pubmed: 26437589
Cancer Res. 2009 Mar 15;69(6):2195-200
pubmed: 19276373
Oncogene. 2012 Feb 23;31(8):978-91
pubmed: 21765474
Nat Cell Biol. 2008 May;10(5):593-601
pubmed: 18376396
Eur Urol. 2017 Apr;71(4):618-629
pubmed: 27568654
Oncotarget. 2017 Jan 24;8(4):5735-5752
pubmed: 27974696
Proc Natl Acad Sci U S A. 2012 Sep 18;109(38):15312-7
pubmed: 22949650
Biochem Biophys Res Commun. 2013 Nov 8;441(1):139-43
pubmed: 24129185
Cancer Med. 2016 Nov;5(11):3300-3309
pubmed: 27730756
PLoS One. 2009;4(3):e4687
pubmed: 19262738
Adv Exp Med Biol. 2014;818:127-53
pubmed: 25001534
Nat Rev Urol. 2013 Aug;10(8):473-82
pubmed: 23712205
Bioessays. 1999 Dec;21(12):1021-30
pubmed: 10580987
Cells. 2020 Aug 25;9(9):
pubmed: 32854238
Nat Rev Cancer. 2004 Jun;4(6):470-80
pubmed: 15170449
Ther Adv Urol. 2013 Dec;5(6):318-29
pubmed: 24294290
Cancer Res. 2003 Aug 15;63(16):5105-13
pubmed: 12941841
Proc Natl Acad Sci U S A. 1998 Nov 24;95(24):14400-5
pubmed: 9826712
Front Oncol. 2019 Dec 10;9:1401
pubmed: 31921658
Biochim Biophys Acta. 2016 Jun;1863(6 Pt A):1238-60
pubmed: 26921821
Int J Urol. 2015 Mar;22(3):242-52
pubmed: 25599923
Mol Biol Cell. 2009 Apr;20(8):2207-17
pubmed: 19225155
Expert Rev Mol Diagn. 2020 Feb;20(2):219-230
pubmed: 31577907
Lab Invest. 2012 Jul;92(7):1084-96
pubmed: 22525428
Oncol Lett. 2018 Aug;16(2):2207-2214
pubmed: 30008920
PLoS One. 2012;7(3):e33729
pubmed: 22442719
Anticancer Drugs. 2009 Mar;20(3):179-84
pubmed: 19396016
Eur Rev Med Pharmacol Sci. 2016;20(1):92-100
pubmed: 26813458
J Cell Sci. 2005 Oct 1;118(Pt 19):4325-6
pubmed: 16179603
PLoS One. 2012;7(10):e46990
pubmed: 23056551
Mol Med. 2001 Apr;7(4):271-82
pubmed: 11471572
PLoS One. 2012;7(4):e35158
pubmed: 22514717
Oncol Rep. 2012 Apr;27(4):1200-6
pubmed: 22159356
BMJ Open. 2015 Jan 22;5(1):e006244
pubmed: 25613953
Cell Cycle. 2014;13(2):227-39
pubmed: 24200968
Int Immunol. 2006 Feb;18(2):233-40
pubmed: 16410314
Prostate. 2019 Jan;79(1):88-95
pubmed: 30194772
Med Clin North Am. 2017 Jul;101(4):787-806
pubmed: 28577627
Sci Rep. 2017 Nov 24;7(1):16308
pubmed: 29176717
Cancer Res. 2011 Apr 1;71(7):2611-21
pubmed: 21330408
Am J Transl Res. 2015 Oct 15;7(10):2053-9
pubmed: 26692949
Eur Urol. 2019 Jan;75(1):88-99
pubmed: 29673712